Artelo Biosciences, Inc. (ARTL) Insider Trading Activity

NASDAQ$1.36+0.04 (3.03%)
Market Cap
$3.08M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
444 of 870
Rank in Industry
263 of 505

ARTL Insider Trading Activity

ARTL Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
–
Sells
$0
0
–

Related Transactions

About Artelo Biosciences, Inc.

Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.

Insider Activity of Artelo Biosciences, Inc.

Over the last 12 months, insiders at Artelo Biosciences, Inc. have bought $0 and sold $0 worth of Artelo Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Artelo Biosciences, Inc. have bought $9,636 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,200 shares for transaction amount of $4,800 was made by Gorgas Gregory D. (Pres, CEO, CFO, Treas & Secr) on 2022‑08‑12.

List of Insider Buy and Sell Transactions, Artelo Biosciences, Inc.

2022-08-12PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
1,200
0.0445%
$4.00
$4,800
-27.57%
2022-08-11PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
1,200
0.0456%
$4.03
$4,836
-26.08%
2021-04-16PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
8,500
0.0366%
$1.15
$9,809
-30.80%
2020-05-15PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
4,200
0.1219%
$1.21
$5,072
-5.00%
2020-05-04PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
4,167
0.1136%
$1.20
$5,000
-9.45%
2020-05-04PurchaseMATSUI CONNIEdirector
41,667
1.1357%
$1.20
$50,000
-9.45%
2019-11-04PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2,400
0.0701%
$2.21
$5,304
-45.78%
2019-11-01PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2,500
0.0823%
$2.28
$5,702
-40.29%
2019-10-31PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2,500
0.0729%
$1.95
$4,875
-38.19%
2019-10-30PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2,600
0.0771%
$1.99
$5,186
-38.50%
2019-10-15PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2,600
0.0793%
$2.05
$5,333
-37.50%
2019-10-11PurchaseGorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2,700
0.0796%
$1.96
$5,296
-36.87%
Total: 12

Insider Historical Profitability

<0.0001%
MATSUI CONNIEdirector
56667
2.4282%
$74,800.4410
<0.0001%
Gorgas Gregory D.Pres, CEO, CFO, Treas & Secr
2400
0.1028%
$3,168.00110
<0.0001%

Historical Insider Profitability vs. Competitors

$1,848,072
66
-14.67%
$3.38M
$13,690,078
47
-70.44%
$3.6M
$1,623,655
34
-17.39%
$4.61M
$1,138,733
28
-4.94%
$4.51M
$8,249,886
17
-47.87%
$2.75M
$360,130
16
-21.17%
$1.57M
$79,536,861
15
-6.81%
$4.49M
$742,412
14
-50.36%
$4.52M
Artelo Biosciences, Inc.
(ARTL)
$105,917
11
-28.06%
$3.08M
$245,000
7
-62.00%
$2.62M
$40,324
6
31.82%
$4.14M
$70,828
6
-57.96%
$2.86M
$726,438
4
-72.85%
$2.44M
$157,740
3
153.95%
$2.59M
$14,530
3
62.23%
$4.44M
$4,773,558
2
-65.58%
$2.06M
$37,000
1
79.42%
$2.81M
$16,800
1
-55.91%
$2.02M
$3,300,000
1
-5.51%
$4.42M

ARTL Institutional Investors: Active Positions

Increased Positions8+66.67%84,255+254.99%
Decreased Positions5-41.67%18,793-56.87%
New Positions6New50,837New
Sold Out Positions5Sold Out18,793Sold Out
Total Postitions15+25%98,505+198.11%

ARTL Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Drw Securities, Llc$22.000.86%17,185+17,185New2025-09-30
Vanguard Group Inc$18.000.7%14,028+14,028New2025-09-30
Morgan Stanley$1.000.06%1,100+1,096+27,400%2025-09-30
Citigroup Inc$1.000.02%477+468+5,200%2025-09-30
Ubs Group Ag$00.01%209+120+134.83%2025-09-30
Fmr Llc$0<0.01%30+29+2,900%2025-09-30
Bank Of America Corp /De/$0<0.01%11+6+120%2025-09-30
Rothschild Investment Llc$00%2+2New2025-09-30
Royal Bank Of Canada$00%100%2025-09-30
Danske Bank A/S$00%0<1Sold Out2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.